COYA
Coya Therapeutics Inc
$
5.760
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.015
Open
5.730
VWAP
5.75
Vol
92.15K
Mkt Cap
117.38M
Low
5.680
Amount
529.42K
EV/EBITDA(TTM)
--
Total Shares
15.22M
EV
87.83M
EV/OCF(TTM)
--
P/S(TTM)
221.51
Coya Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in developing treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Its initial developmental programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases of high unmet medical need. Its diversified candidate pipeline includes both ex vivo and in vivo approaches. Its product candidate pipeline is based on its three therapeutic modalities. The product candidates utilizing its Treg-enhancing biologics are collectively referred to as the 300 Series. The product candidates utilizing its Treg-derived exosomes are collectively referred to as the 200 Series. The product candidates utilizing its autologous Treg cell therapy are collectively referred to as the 100 Series. The Company's 300 Series product candidates include COYA 301 and COYA 302.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
154.29K
+7812.31%
-0.466
+5.91%
668.57K
-80.48%
-0.439
+143.65%
--
--
-0.233
-10.44%
Estimates Revision
The market is revising Downward the revenue expectations for Coya Therapeutics, Inc. (COYA) for FY2025, with the revenue forecasts being adjusted by -0.4% over the past three months. During the same period, the stock price has changed by -10.00%.
Revenue Estimates for FY2025
Revise Downward
-0.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-5.57%
In Past 3 Month
Stock Price
Go Down
-10.00%
In Past 3 Month
4 Analyst Rating
Wall Street analysts forecast COYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COYA is 17.25 USD with a low forecast of 15.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.760
Low
15.00
Averages
17.25
High
20.00
Current: 5.760
Low
15.00
Averages
17.25
High
20.00
Lake Street
Buy
maintain
$16 -> $17
2025-11-05
New
Reason
Lake Street
Price Target
$16 -> $17
2025-11-05
New
maintain
Buy
Reason
Lake Street raised the firm's price target on Coya Therapeutics to $17 from $16 and keeps a Buy rating on the shares after the company released preclinical in vivo neuroinflammation data for COYA-303 consistent with earlier in vitro preclinical results released by Coya.
Lake Street
NULL -> Buy
initiated
$16
2025-07-09
Reason
Lake Street
Price Target
$16
2025-07-09
initiated
NULL -> Buy
Reason
Lake Street initiated coverage of Coya Therapeutics with a Buy rating and $16 price target. The firm says the company's anti-inflammation platform utilizes a disease pathway agnostic approach to increase the number and function of regulatory T cells. The evidence supporting a therapeutic anti-inflammatory benefit of Coya's low dose IL-2 is strong, the analyst tells investors in a research note.
Lucid Capital
Elemer Piros
Buy
initiated
$20
2025-06-09
Reason
Lucid Capital
Elemer Piros
Price Target
$20
2025-06-09
initiated
Buy
Reason
Lucid Capital analyst Elemer Piros initiated coverage of Coya Therapeutics with a Buy rating and $20 price target. Coya is developing a pioneering approach to treat neurodegenerative disorders by addressing inflammation in the brain, the analyst tells investors in a research note. The firm sees an unmet need in amyotrophic lateral sclerosis.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18
2025-04-22
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18
2025-04-22
Maintains
Strong Buy
Reason
Atea Pharmaceuticals (AVIR) announced the appointment of Howard Berman, Ph.D. to its Board of Directors. Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. The Company is adding Dr. Berman to the Board as part of its entry into an agreement with Bradley Radoff and Michael Torok. In connection with the Agreement, the Radoff-JEC Group has withdrawn its slate of nominated director candidates and has agreed to vote all of the shares it collectively owns in favor of each of Atea's Board nominees at the 2025 Annual Meeting. The Company also announced that Franklin Berger has informed the Company of his intention not to stand for reelection at Atea's 2027 Annual Meeting of Stockholders. Berman, Ph.D., is the Founder, Executive Chairman and former CEO of Coya Therapeutics (COYA).
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$18
2025-03-27
Reason
D. Boral Capital
Jason Kolbert
Price Target
$18
2025-03-27
Maintains
Strong Buy
Reason
Chardan Capital
Keay Nakae
Strong Buy
Maintains
$14
2025-03-20
Reason
Chardan Capital
Keay Nakae
Price Target
$14
2025-03-20
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Coya Therapeutics Inc (COYA.O) is -3.63, compared to its 5-year average forward P/E of -7.24. For a more detailed relative valuation and DCF analysis to assess Coya Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.24
Current PE
-3.63
Overvalued PE
1.76
Undervalued PE
-16.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.79
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.90
Undervalued EV/EBITDA
-4.48
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
15.72
Current PS
5.77
Overvalued PS
24.97
Undervalued PS
6.47
Financials
Annual
Quarterly
FY2025Q2
YoY :
-95.22%
163.62K
Total Revenue
FY2025Q2
YoY :
+98.22%
-6.41M
Operating Profit
FY2025Q2
YoY :
+110.78%
-6.09M
Net Income after Tax
FY2025Q2
YoY :
+89.47%
-0.36
EPS - Diluted
FY2025Q2
YoY :
+26.51%
-5.77M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
-3.89K
FCF Margin - %
FY2025Q2
YoY :
+4312.66%
-3.73K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
372.4K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
COYA News & Events
Events Timeline
2025-11-04 (ET)
2025-11-04
09:02:27
Coya Therapeutics Reveals Findings from In Vivo Animal Study of COYA 303
2025-10-24 (ET)
2025-10-24
06:33:39
Coya Therapeutics Sets Price for $3.64M Spot Secondary at $5.50
2025-10-23 (ET)
2025-10-23
16:33:31
Coya Therapeutics Reveals Common Stock Offering, Amount Not Disclosed
Sign Up For More Events
Sign Up For More Events
News
8.5
10-24NewsfilterCoya Therapeutics Reveals Pricing for Increased $20 Million Public Offering of Common Stock
8.5
10-24SeekingAlphaCoya Therapeutics Declines Following $20M Stock Offering Announcement
8.5
10-23NewsfilterCoya Therapeutics Unveils Plans for Public Offering of Common Stock
Sign Up For More News
People Also Watch
FAQ
What is Coya Therapeutics Inc (COYA) stock price today?
The current price of COYA is 5.76 USD — it has decreased -0.17 % in the last trading day.
What is Coya Therapeutics Inc (COYA)'s business?
What is the price predicton of COYA Stock?
What is Coya Therapeutics Inc (COYA)'s revenue for the last quarter?
What is Coya Therapeutics Inc (COYA)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Coya Therapeutics Inc (COYA)'s fundamentals?
How many employees does Coya Therapeutics Inc (COYA). have?